The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer’s offenses. Researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things.

Martin Morgan, PhD, has joined Roswell Park Comprehensive Cancer Center as an Associate Member of the Department of Biostatistics and Bioinformatics. He remains Director of the R/Bioconductor Project, an open-source, open-development software system created to provide tools for high-throughput analysis and comprehension of genomic data — a resource now based at Roswell Park.